'Stealth' lipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug.

[1]  C. Pouton,et al.  An in vitro digestion test that reflects rat intestinal conditions to probe the importance of formulation digestion vs first pass metabolism in Danazol bioavailability from lipid based formulations. , 2014, Molecular pharmaceutics.

[2]  Hywel D Williams,et al.  Strategies to Address Low Drug Solubility in Discovery and Development , 2013, Pharmacological Reviews.

[3]  A. Gabizon,et al.  Polyethylene Glycol-Coated (Pegylated) Liposomal Doxorubicin , 2012, Drugs.

[4]  A. Müllertz,et al.  Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion. , 2012, Molecular pharmaceutics.

[5]  A. Müllertz,et al.  Toward the establishment of standardized in vitro tests for lipid-based formulations, part 1: method parameterization and comparison of in vitro digestion profiles across a range of representative formulations. , 2012, Journal of pharmaceutical sciences.

[6]  G. Edwards,et al.  Lipid digestion as a trigger for supersaturation: evaluation of the impact of supersaturation stabilization on the in vitro and in vivo performance of self-emulsifying drug delivery systems. , 2012, Molecular pharmaceutics.

[7]  C. Prestidge,et al.  Hybrid nanomaterials that mimic the food effect: controlling enzymatic digestion for enhanced oral drug absorption. , 2012, Angewandte Chemie.

[8]  T. Rades,et al.  Influence of lipid composition and drug load on the In Vitro performance of self-nanoemulsifying drug delivery systems. , 2012, Journal of pharmaceutical sciences.

[9]  L. Dong,et al.  Enhanced bioavailability of a poorly water-soluble weakly basic compound using a combination approach of solubilization agents and precipitation inhibitors: a case study. , 2012, Molecular pharmaceutics.

[10]  Juan de Vicente,et al.  Controlling lipolysis through steric surfactants: new insights on the controlled degradation of submicron emulsions after oral and intravenous administration. , 2012, International journal of pharmaceutics.

[11]  David Julian McClements,et al.  Inhibition of lipase-catalyzed hydrolysis of emulsified triglyceride oils by low-molecular weight surfactants under simulated gastrointestinal conditions. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[12]  J. Vicente,et al.  Investigating the effect of surfactants on lipase interfacial behaviour in the presence of bile salts , 2011 .

[13]  F. Fotiadu,et al.  Effects of Surfactants on Lipase Structure, Activity, and Inhibition , 2011, Pharmaceutical Research.

[14]  T. Rades,et al.  Precipitation of a poorly soluble model drug during in vitro lipolysis: characterization and dissolution of the precipitate. , 2010, Journal of pharmaceutical sciences.

[15]  W. Weitschies,et al.  Effects of non-ionic surfactants on in vitro triglyceride digestion and their susceptibility to digestion by pancreatic enzymes. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[16]  T. Rades,et al.  Silica nanoparticles to control the lipase-mediated digestion of lipid-based oral delivery systems. , 2010, Molecular pharmaceutics.

[17]  C. Pouton,et al.  Design of lipid-based formulations for oral administration of poorly water-soluble drugs: precipitation of drug after dispersion of formulations in aqueous solution. , 2009, Journal of pharmaceutical sciences.

[18]  F. Carrière,et al.  In Vitro Gastrointestinal Lipolysis of Four Formulations of Piroxicam and Cinnarizine with the Self Emulsifying Excipients Labrasol® and Gelucire® 44/14 , 2009, Pharmaceutical Research.

[19]  Jean-David Rodier,et al.  Lipolysis of the semi-solid self-emulsifying excipient Gelucire 44/14 by digestive lipases. , 2008, Biochimica et biophysica acta.

[20]  B. Kelly,et al.  The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers. , 2008, Molecular pharmaceutics.

[21]  C. Pouton,et al.  Enhancing intestinal drug solubilisation using lipid-based delivery systems. , 2008, Advanced drug delivery reviews.

[22]  G. Edwards,et al.  Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs. , 2008, Journal of pharmaceutical sciences.

[23]  C. Goddeeris,et al.  Correlation between digestion of the lipid phase of smedds and release of the anti-HIV drug UC 781 and the anti-mycotic drug enilconazole from smedds. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[24]  C. Porter,et al.  Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs , 2007, Nature Reviews Drug Discovery.

[25]  B. Boyd,et al.  Examination of the impact of a range of Pluronic surfactants on the in‐vitro solubilisation behaviour and oral bioavailability of lipidic formulations of atovaquone , 2006, The Journal of pharmacy and pharmacology.

[26]  Ben J. Boyd,et al.  Susceptibility to Lipase-Mediated Digestion Reduces the Oral Bioavailability of Danazol After Administration as a Medium-Chain Lipid-Based Microemulsion Formulation , 2004, Pharmaceutical Research.

[27]  G. Edwards,et al.  Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: studies with halofantrine. , 2004, Journal of pharmaceutical sciences.

[28]  Ben J. Boyd,et al.  Drug Solubilization Behavior During in Vitro Digestion of Simple Triglyceride Lipid Solution Formulations , 2004, Pharmaceutical Research.

[29]  Ben J Boyd,et al.  Probing drug solubilization patterns in the gastrointestinal tract after administration of lipid-based delivery systems: a phase diagram approach. , 2004, Journal of pharmaceutical sciences.

[30]  R. Strickley.  Solubilizing Excipients in Oral and Injectable Formulations , 2004, Pharmaceutical Research.

[31]  F. Bates,et al.  Polymer vesicles in vivo: correlations with PEG molecular weight. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[32]  B. He,et al.  Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[33]  R. Müller,et al.  'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. , 2000, Colloids and surfaces. B, Biointerfaces.

[34]  C. Lipinski.  Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[35]  G. Edwards,et al.  Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine , 1998 .

[36]  Samuel Zalipsky,et al.  Introduction to Chemistry and Biological Applications of Poly(ethylene glycol) , 1997 .

[37]  Jonathan Kenneth Embleton,et al.  Influence of lipolysis on drug absorption from the gastro-intestinal tract , 1997 .

[38]  Colin W. Pouton,et al.  Formulation of self-emulsifying drug delivery systems , 1997 .

[39]  A A Bogdanov,et al.  Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. , 1994, Biochimica et biophysica acta.

[40]  T. Allen,et al.  Pharmacokinetics of stealth versus conventional liposomes: effect of dose. , 1991, Biochimica et biophysica acta.

[41]  R. A. McGill,et al.  New Polyethylene Glycols for Biomedical Applications , 1991 .

[42]  V. Torchilin,et al.  Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo , 1991, FEBS letters.

[43]  B. Aungst.  Structure/Effect Studies of Fatty Acid Isomers as Skin Penetration Enhancers and Skin Irritants , 1989, Pharmaceutical Research.

[44]  Colin W. Pouton,et al.  Self-emulsifying drug delivery systems: assessment of the efficiency of emulsification , 1985 .

[45]  T. R. Bates,et al.  Bioavailability of micronized griseofulvin from corn oil-in-water emulsion, aqueous suspension, and commercial tablet dosage forms in humans. , 1975, Journal of pharmaceutical sciences.

[46]  R Holm,et al.  Supersaturated Self-Nanoemulsifying Drug Delivery Systems (super-SNEDDS) , 2012 .

[47]  Colin W. Pouton,et al.  Self-Emulsifying Drug Delivery Systems: Formulation and Biopharmaceutic Evaluation of an Investigational Lipophilic Compound , 2004, Pharmaceutical Research.

[48]  V. Torchilin.  Polymer-coated long-circulating microparticulate pharmaceuticals. , 1998, Journal of microencapsulation.

[49]  M. Papisov,et al.  Why do Polyethylene Glycol-Coated Liposomes Circulate So Long?: Molecular Mechanism of Liposome Steric Protection with Polyethylene Glycol: Role of Polymer Chain Flexibility , 1994 .

[50]  W. C. Griffin.  Classification of surface-active agents by "HLB" , 1946 .